CS210406C3 R001 OCT2023



Gamzook'aamin aakoziwin

FIGHTING CANCER TOGETHER

WWW. FIGTHINGCANCERTOGETHER.CA

TOP 5
facts about the partnership

The SON – Bruce Power Medical Isotopes Partnership

1. SON and Bruce Power finalized the New Isotope Marketing and Collaboration Agreement represented by the partnership name, Gamzook'aamin aakoziwin in 2019.

2. The name "Gamzook'aamin aakoziwin" translates to "We are Teaming up to Fight the Sickness" and was developed in consultation with Neyaashiinigmiing knowledge holder and language speaker Polly Keeshig-Tobias.

3. The artwork for Gamzook'aamin Aakoziwin was developed by Emily Kewageshig, an artist and member of Saugeen Ojibway Nation, and represents all people working together towards healing.

4. The isotope that Bruce Power is producing is called lutetium-177 or lu-177 and it is used for both diagnosis and treatment of specialized brain, prostate and breast cancers.

5. Each of the SON Communities will earn an equal annual return from lu-177 sales, to support community development and well-being initiatives.

WWW. FIGTHINGCANCERTOGETHER.CA

Did You Know?

Lu-177 is not the first medical isotope produced at Bruce Power. The Bruce B reactors have been producing medical cobalt-60 (used for sterilization of medical equipment) for over 30 years. Currently, Bruce Power's cobalt-60 sterilizes 40% of the world's single-use medical devices.



WWW. FIGTHINGCANCERTOGETHER.CA

CS210406C2 R001 OCT2023

TOP 5
facts about lutetium-177

Medical Isotope Lutetium-177

1. The Isotope Production System (IPS) installed in Bruce Power's Unit 7 is currently producing lutetium-177.

2. Lu-177 is a medical isotope produced by irradiating a different stable element called ytterbium-176 in the IPS for 2 weeks until the composition of the element changes, creating lu-177.

3. Lu-177 is used in targeted radionuclide therapy to diagnose (image) and treat neuroendocrine tumours, prostate and breast cancer.

4. Lu-177 delivers a radioactive dose to the cancer cells while leaving the body's healthy cells unaffected.

5. Lu-177 is in high demand and low supply since the decommissioning of the National Research Universal reactor (NRU) in 2018, which produced the bulk of Canada's lu-177. The IPS installed at Bruce Power is capable of producing large volumes of lu-177, due to the constant operations of the reactor.

CS2104066C1 R001 OCT2023

Lutetium-177 Production Process



WWW. FIGTHINGCANCERTOGETHER.CA

TOP 5
facts about lutetium-177 production

Lutetium-177 Production at Bruce Power

1. Bruce Power installed a revolutionary "Isotope Production System" (IPS) in Unit 7 and began production and distribution of lutetium-177 (lu-177) in 2022.

2. The IPS is designed to produce lu-177 while simultaneously generating electricity. Bruce Power has partnered with Isogen (a Kinectrics and Framatome company) to lead system implementation, and with ITM to process and distribute medical-grade lu-177.

3. The IPS at Bruce Power is a game-changer for lu-177 production, providing a reliable supply of isotopes, improving local and global access to these cancer fighting tools.

4. The production of Lu-177 does not create a new source of nuclear waste. All materials are either used for treatment of cancer patients or are recycled and used to produce more lu-177.

5. The IPS does not change the existing footprint of Bruce Power's operations, and does not result in any new environmental impacts or changes.